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Abstract 
Background: The central nervous system (CNS) is protected by several barriers, including the blood–brain (BBB) 
and blood‑cerebrospinal fluid (BCSFB) barriers. Understanding how cancer cells circumvent these protective barri‑
ers to invade the CNS is of crucial interest, since brain metastasis during cancer is often a fatal event in both children 
and adults. However, whereas much effort has been invested in elucidating the process of tumor cell transmigration 
across the BBB, the role of the BCSFB might still be underestimated considering the significant number of menin‑
geal cancer involvement. Our work aimed to investigate the transmigration of neuroblastoma cells across the BCSFB 
in vitro.
Methods: We used an inverted model of the human BCSFB presenting proper restrictive features including adequate 
expression of tight‑junction proteins, low permeability to integrity markers, and high trans‑epithelial electrical resist‑
ance. Two different human neuroblastoma cell lines (SH‑SY5Y and IMR‑32) were used to study the transmigration 
process by fluorescent microscopy analysis.
Results: The results show that neuroblastoma cells are able to actively cross the tight human in vitro BCSFB model 
within 24 h. The presence and transmigration of neuroblastoma cancer cells did not affect the barrier integrity within 
the duration of the experiment.
Conclusions: In conclusion, we presume that the choroid plexus might be an underestimated site of CNS invasion, 
since neuroblastoma cell lines are able to actively cross a choroid plexus epithelial cell layer. Further studies are war‑
ranted to elucidate the molecular mechanisms of tumor cell transmigration in vitro and in vivo.
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Background
Neuroblastoma is a common extracranial pediatric solid 
tumor, arising from the sympathetic nervous system. 
At the time of diagnosis, more than half of the patients 
already exhibit metastases in distant organs, including 
lymph nodes, bone marrow, bone and other organs. Even 
if central nervous system (CNS) involvement is rarely 
described in neuroblastoma and restricted to tumor 
relapse, its frequency is increasing and its prognosis 
is dismal [1]. Efforts have been made to develop treat-
ments for CNS metastases, but they are generally inef-
fective in preventing progression and subsequent death 
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[2]. The pattern of spread is mostly believed to occur via 
the hematogenous route, implying that circulating cancer 
cells reach the CNS after crossing the interfaces exist-
ing between the blood and the brain. Among these, the 
blood–brain barrier (BBB) lies in the restrictive micro-
vascular walls, whereas the blood-cerebrospinal fluid 
barrier (BCSFB) is formed by the choroid plexus epithe-
lial cells [3]. Many studies have focused on the migration 
of cancer cells through the blood–brain barrier, whereas 
the BCSFB is underestimated as a potential route to 
reach the CNS. In the frame of neuroblastoma, CNS 
metastatic lesions are indeed not only parenchymal, but 
intraventricular lesions and meningeosis have also been 
described [4, 5]. Our aim was to elucidate the migra-
tory potential of neuroblastoma cells to cross the intact 
BCSFB. For this purpose, we studied the transmigration 
of two neuroblastoma cell lines—IMR32 and SH-SY5Y 
cells—through a well-established human in vitro BCSFB 
model. Our results show that these neuroblastoma cell 
lines could actively cross the choroid plexus epithelium 
within 24 h to a similar extent, and that the interactions 
with cancer cells did not cause a breakdown of the cel-
lular barrier.
Results
IMR32 and SH‑SY5Y cells can cross the intact human 
in vitro BCSFB within 24 h and do not affect its overall 
integrity
The transmigration of neuroblastoma cell lines was 
studied through the human BCSFB in  vitro (Fig.  1), 
which consists of polarized HIBCPP cells [6]. For con-
venience and as already described [6], we used the 
inverted model where HIBCPP cells are cultivated on 
the bottom of the inserts, so that the blood side cor-
responds to the upper compartment (Fig.  1a). In basal 
conditions, choroid plexus epithelial cell cultures exhib-
ited high electrical resistance (Fig.  1c, 269.9 ±  13.5  Ω 
cm2) and low permeability to Lucifer Yellow  (LY) 
integrity marker (Fig. 1d, 0.09 ± 0.01 × 10−3 cm/min), 
demonstrating the formation of a restrictive barrier. 
Neuroblastoma cells were harvested, dissociated and 
incubated in the upper compartment of inserts alone or 
inserts with HIBCPP cells (Fig.  1a), and 24  h later the 
number of transmigrated cells was assessed by fluores-
cence measurements.
Between 0.14 and 0.22 % of neuroblastoma cells effec-
tively transmigrated through the barrier and no sig-
nificant difference could be seen between IMR32 and 
SH-SY5Y cell lines (Fig. 1b; 0.14 ± 0.02 and 0.22 ± 0.05 %, 
respectively). A larger proportion of neuroblastoma 
cells could reach the lower compartment in the absence 
of HIBCPP cells (Fig.  1b; 2.94 ±  0.10  % of IMR32 cells 
and 3.37 ± 0.33 % of SH-SY5Y), showing that the barrier 
formed by HIBCPP cells restricted cancer cell migration. 
No impairment of the barrier integrity could be seen after 
transmigration experiments, concerning either the TEER 
(Fig. 1c) or the permeability to LY (Fig. 1d), regardless of 
the neuroblastoma cell line used. This data suggests that 
the epithelial barrier function of HIBCPP layer was not 
impaired in presence of IMR32 and SH-SY5Y neuroblas-
toma cells.
When the barrier formed by HIBCPP cells was 
reversibly impaired by a pretreatment with the actin 
microfilament-disrupting agent Cytochalasin D, the 
transmigration rate of both neuroblastoma cell lines was 
increased compared to untreated filters (Additional file 1: 
Figure 1).
The different steps of neuroblastoma cell transmigration 
through the BCSFB in vitro
To observe transmigrating neuroblastoma cells at differ-
ent stages, experiments were stopped after 6 h by fixing 
the samples before immunocytochemical analysis and 
subsequent fluorescence microscopy observation (Fig. 2). 
For each set of pictures (a, b and c), upper panels indi-
cate the localizations of cancer cells within the HIBCPP 
layer corresponding to the following pictures (middle 
and lower panels). Photographs show the layer formed by 
HIBCPP cells on the lower side of the filters (Fig. 2, two 
middle panels; apical and basolateral sides indicated by 
‘A’ and ‘B’, respectively), and CellTracker™-stained neu-
roblastoma SH-SY5Y cells during (Fig.  2a, b) and after 
(Fig. 2c) trans-epithelial migration.
Figure  2a shows a neuroblastoma cell progressing 
within the epithelium, seemingly surrounded by the epi-
thelial filamentous actin cytoskeleton (Fig.  2a, middle 
panels, arrowheads). The 3D reconstruction of a mag-
nification from an apical point of view (Fig.  2a, lower 
panel) shows the rounded neuroblastoma cell progress-
ing within the layer of epithelial cells, just below a tight 
junction, but the route taken by the cancer cell (paracel-
lular or transcellular) cannot be definitely determined. In 
Fig. 2b, a neuroblastoma cell is also progressing through 
the barrier but exhibits an elongated shape. It is sending 
a possible projection (Fig. 2b, middle panels, arrows) to 
the apical side of the epithelium, through the tight junc-
tions (Fig. 2b, lower panel; 3D reconstruction of a magni-
fication from a lateral point of view). This data suggests 
that neuroblastoma cells can undergo paracellular trans-
epithelial migration in order to cross the BCSFB. Finally, 
Fig. 2c represents a neuroblastoma cell having completed 
the transmigration process because it appears on the sur-
face of the epithelial layer, expressing continuous tight 
junctions (Fig. 2c, middle panels). The 3D reconstruction 
from an apical point of view (Fig. 2c, lower panel) shows 
the cancer cell lying at the apical side of the barrier, with 
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a continuous tight junction staining underneath the neu-
roblastoma cell (Additional file 2: Figure 2).
Discussion
The improvement of treatment strategies has allowed for 
remissions in a large subset of high-risk neuroblastoma 
patients, but in parallel, an increasing number of chil-
dren will later develop focal and metastatic relapse [7, 
8]. Among the involved organs, the brain is one of the 
most common sites of isolated relapse in neuroblastoma 
patients [1, 7], and up to 16 % of patients develop CNS 
metastases [1, 9, 10]. The prognosis of these patients is 
still dismal despite extensive therapeutic efforts [1, 8, 
11]. Therefore, understanding how neuroblastoma cells 
manage to reach the CNS despite its protective barri-
ers is of utmost importance. The blood–brain barrier 
(BBB), located in brain microvascular endothelial cells, 
is thought to be the main entry gate for cancer cells into 
the CNS via the hematogenous route [12]. In neuroblas-
toma, patients not only develop parenchymal metastases, 
Fig. 1 The blood‑cerebrospinal fluid barrier (BCSFB) in vitro model (a) used for transmigration experiments (b) and effect of the transmigration 
process on the barrier function (c, d). a The BCSFB model is based on the culture of human choroid plexus papilloma cells (HIBCPP cells) on the 
lower surface of the inserts, so that the upper side mimics the blood compartment and the lower one the CSF compartment. For the transmigration 
experiment, neuroblastoma cells were dissociated and intracellularly stained using BCECF‑AM (1), before being seeded in the upper compartment 
(2). At the end of the experiment (3), the number of transmigrated cells was assessed by fluorescence measurements, and the barrier integrity was 
evaluated by measuring the trans‑epithelial electrical resistance (TEER) and the permeability of the barrier to Lucifer Yellow (LY, integrity marker). b 
Percentage of transmigrated neuroblastoma cells (having reached the lower compartments after crossing filters alone, or filters + HIBCPP layer), as 
assessed by fluorescence measurements. c TEER values (in Ω cm2) before and after the transmigration of IMR32 and SH‑SY5Y cells. d Permeability 
coefficient (Pe, in cm/min) for LY measured on control filters and after the transmigration of IMR32 and SH‑SY5Y cells. N.S. non significant
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Fig. 2 Fluorescent microscopy study of neuroblastoma cell transmigration through the BCSFB in vitro. Six hours after seeding SH‑SY5Y neuroblas‑
toma cells in the upper compartments of the filters, samples were fixed and stained for occludin (tight junction protein, in green), F‑actin (cytoskel‑
eton, in pink) and DAPI (nuclei, in blue). Neuroblastoma cells had previously been stained with a fixable CellTracker™ (in yellow). As represented for 
each set of pictures (upper panels), photographs show representative neuroblastoma cells at different stages of the transmigration process (during, 
a, b; and after, c) through the epithelial layer formed by HIBCPP cells on the lower side of the filters (two middle panels, en face Apotome® microscopy 
images showing all channels and selected channels, respectively; lower panels, 3D reconstructions from an apical—a and c—and a lateral point 
of view—b). Apical and basolateral sides of the barriers are indicated by ‘A’ and ‘B’, respectively. In a the arrowheads indicate the phalloidin‑stained 
filamentous actin cytoskeleton surrounding the transmigrating neuroblastoma cell. In b the arrows point to a possible projection sent by the trans‑
migrating cancer cell through tight junctions. In c arrows indicate the neuroblastoma cell having reached the apical surface of the epithelial barrier. 
Scale bar as indicated
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but also leptomeningeal and intraventricular lesions have 
been described [4]. In these patients, it might well be that 
the tumor cells have transmigrated through the BCSFB, 
after having crossed the fenestrated capillaries of the 
choroid plexus. However, rare studies have considered 
the BCSFB as a potential route for cancer cells into the 
brain [13], and therefore the significance of this phenom-
enon has not been explored until now.
Since in vitro models prove useful in deciphering cel-
lular mechanisms involved in cancer cell-brain barrier 
interactions [14, 15], our aim was to use a human in vitro 
BCSFB model for studying the migration potential of 
neuroblastoma cells through the BCSFB. As already 
described [6], this human BCSFB model exhibits proper 
barrier features, as shown by its TEER and low perme-
ability to LY. The present results are the first to demon-
strate that two neuroblastoma cell lines (IMR-32 and 
SH-SY5Y) are able to cross a choroid plexus epithelial cell 
layer, representing the anatomical basis of the BCSFB. 
Transmigrating neuroblastoma cells could be detected 
at different stages of the process by fluorescence micros-
copy imaging and 3-dimensional reconstruction. No 
impairment in the barrier integrity could be observed 
after 6–24  h of contact and no focal destruction of the 
epithelial layer could be observed around the transmi-
grating neuroblastoma cells; therefore we assume an 
active transmigration process of neuroblastoma cells 
through the choroid plexus epithelial cell layer. From 
fluorescence microscopy imaging we cannot definitely 
distinguish a transcellular from a paracellular route. 
Although the significantly increased transmigration rate 
in case of BCSFB disruption by cytochalasin D argues for 
a paracellular way, electron microscopy imaging is war-
ranted to gain further insights into this process. Previous 
studies have highlighted some alterations of endothe-
lial biomechanical properties by cancer cells, involving 
actin  cytoskeletal remodeling via Rho kinase signaling 
[16, 17]. The described rearrangement of endothelial 
actin filaments can promote the trans-endothelial migra-
tion of cancer cells by impacting tight junction assembly 
[17]. Similar processes might occur during the trans-epi-
thelial migration of neuroblastoma cells herein described. 
Different molecules secreted by cancer cells are able to 
influence neighboring cells’ phenotype, in particular at 
the level of the cellular barriers with which they inter-
act during the metastatic process [18]. Among these, 
transforming growth factor beta-1, which is secreted by 
neuroblastoma cells [19], can promote the extravasation 
process by inducing actin cytoskeleton reorganization 
[18, 20, 21]. Recently, microRNA-181c-containing extra-
cellular vesicles secreted by breast cancer cell lines have 
been shown to induce BBB disruption via actin micro-
filament disorganization [22]. It cannot be excluded that 
neuroblastoma cells could cause cytoskeleton changes in 
choroid plexus epithelium by secreting such vesicles.
Brain metastases of extracranial malignancies are not 
restricted to parenchymal lesions. Metastases within the 
choroid plexus or the ventricles as well as leptomeningeal 
tumor spread have been described both in neuroblastoma 
[4] and various other malignancies in children and adults 
[23–25]. In these patients, the choroid plexus might 
have been an entry site of tumor cells to the CNS [23], 
with circulating cancer cells migrating from the lumen 
of the fenestrated choroidal capillaries to that of ventri-
cles. Concerning adhesion to and transmigration across 
endothelial cells, cancer cells share many mechanisms 
with leukocytes including binding to selectins, integrins, 
and immunoglobulin-like cell adhesion molecules to 
invade various organs [18]. Since the epithelial cells of the 
BCSFB share the expression of many of these adhesion 
molecules with BBB endothelial cells [26, 27], and these 
cellular interactions are—at least in part—responsible for 
tumor cell adhesion to and transmigration through the 
BBB [28], we hypothesize that the BCSFB within the cho-
roid plexus might represent a relevant site of tumor inva-
sion to the CNS. However, most previous studies focused 
on the molecular and cellular interaction of tumor cells 
with the endothelial cells of the BBB [14, 15, 29], and 
therefore the role of the choroid plexus epithelial cells 
in the development of brain metastases still needs to be 
addressed. In this regard, human in  vitro models of the 
BCSFB hold out the prospect of contributing significantly 
to our knowledge of molecular and cellular interactions 
between tumor cells and choroid plexus epithelial cells.
Conclusions
We herein demonstrate for the first time that neuro-
blastoma cells are able to actively cross the BCSFB in 
a human in  vitro model. These results indicate that the 
choroid plexus may be an underestimated site of tumor 
cell invasion to the CNS. To further elucidate underly-
ing molecular mechanisms, in vitro models are powerful 
tools in deciphering cellular interactions of cancer cells 
and brain barriers in neuroblastoma, as well as in other 
malignancies that cause brain metastases.
Methods
BCSFB in vitro model
The BCSFB model is based on the cultivation of human 
choroid plexus papilloma cells (known as HIBCPP) 
on the lower surface of cell culture inserts, as already 
described [6] (Fig.  1a). In brief, HIBCPP were cultured 
in DMEM/HAM’s F12 1:1 (Ref. 31330, Gibco) supple-
mented with 15 % (v/v) heat-inactivated fetal calf serum 
(FCS), 4  mM l-Glutamine, 5  mg mL−1 insulin (Ref. 
I9278, Sigma), 100 U mL−1 penicillin and 100 mg mL−1 
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streptomycin (HIBCPP-medium with 15  % FCS). Cells 
were seeded on the lower surface of cell culture inserts 
(ThinCert™ Cell Culture Inserts for 24-well plates, pore 
diameter 3.0 µm; Ref. 662631, Greiner Bio-One, Fricken-
hausen, Germany) that were flipped over and placed in 
medium-flooded 12-well plates. Cells were fed the fol-
lowing day, and the filters were flipped over again and 
placed in a 24-well plate 2 days after seeding. Cell culture 
was continued in HIBCPP-medium containing 1 % FCS 
to increase TEER. When the TEER reached at least 250 
Ω cm2, experiments could be launched.
Cultivation of neuroblastoma cell lines
Human neuroblastoma cell lines SH-SY5Y and IMR32 
were purchased from the European Collection of Cell 
Cultures (Cat n° 94030304 and 86041809, respectively). 
They were cultured in vitro under standard culture con-
ditions (37 °C, 5 % CO2 under humidified atmosphere) in 
RPMI 1640 medium (Ref. F1215, Biochrom AG) supple-
mented with 10 % FCS, 4 mM l-Glutamine (Ref. 25030, 
Gibco), 1 % (v/v) non-essential amino acids (Ref. 11140, 
Gibco), 100 U mL−1 penicillin and 100  µg.mL−1 strep-
tomycin. Medium was renewed every 2–3  days. Before 
reaching confluence, cells were routinely harvested for 
passaging using 0.25  % trypsin—0.02  % EDTA (ethylen-
ediaminetetraacetic acid) solution (Ref. 25200, Gibco).
Trans‑epithelial electrical resistance (TEER) measurements
The TEER of HIBCPP cultures grown on inserts was 
measured using an epithelial tissue Volt-Ohm Meter 
using the STX-2 electrode system (Millicell ERS-2, Mil-
lipore, Schwalbach, Germany), before and after each 
transmigration experiment. The values measured for 
empty filters (or for filters only containing neuroblastoma 
cells in the case of transmigration experiment) were sub-
tracted from the overall TEER values, in order to con-
sider the resistance of the HIBCPP layer itself.
Transmigration assays
Transmigration experiments were performed using the 
same medium in the upper and lower compartments 
(serum-free medium containing 0.5  % (w/v) Bovine 
Serum Albumin, BSA).
When experiments were carried out to determine the 
amount of transmigrated cells after 24 h, neuroblastoma 
cells were harvested, dissociated and labelled with the 
cell-permeant fluorescent dye BCECF-AM (2′,7′-Bis-
(2-Carboxyethyl)-5-(and-6)-Carboxyfluorescein, Ace-
toxymethyl Ester), before being added to the upper 
compartment of the inserts, which represents the blood 
compartment in this inverted BCSFB model (Fig.  1a; 
200,000 neuroblastoma cells added per insert). In paral-
lel, the same number of neuroblastoma cells was added 
to the upper compartments of inserts alone, to assess 
the migration rate in the absence of any cellular barrier. 
After 24 h, the fluid in the lower compartments was cen-
trifuged (5  min at 300×g) to pellet neuroblastoma cells 
located at the bottom of the wells. These cells were lysed 
using 1  % (w/v) Triton X-100 in PBS and their amount 
determined by fluorescence measurement with a Tecan 
200 M Infinite Multiwell reader.
For the experiments that aimed at observing the trans-
migration process using immunocytochemistry (see next 
paragraph), neuroblastoma cells were instead loaded with 
Cell Tracker Green CMFDA (fixable dye) according to 
manufacturer’s instruction (Ref. C7025, Invitrogen). In 
this case, the experiment was stopped after 6–8 h.
Immunocytochemistry
At the end of the transmigration experiment, cells were 
fixed with 4 % formaldehyde, diluted in PBS-CMF (phos-
phate-buffered saline, calcium- and magnesium-free), for 
10  min and rinsed twice with PBS-CMF before cutting 
the membranes. They were subsequently permeabilized 
with 0.5 % (w/v) Triton X-100 diluted in PBS-CMF con-
taining 1 % (w/v) BSA (PBS-CMF-1 %BSA) for 1 h. After 
rinsing three times with PBS-CMF-1  %BSA, samples 
were blocked with PBS-CMF-1  % BSA for 30  min and 
were then incubated with the primary antibody overnight 
at 4  °C (rabbit anti-occludin, Ref. 71-1500, Invitrogen; 
dilution 1/200 in PBS-CMF-1 %BSA).
The following day, samples were rinsed three times with 
PBS-CMF-1  %BSA, and incubated with the secondary 
antibody for 1 h at RT (chicken anti-rabbit IgG 594, Ref. 
A21442, Invitrogen, diluted 1/500 in PBS-CMF-1 %BSA).
After two rinsing steps with PBS-CMF-1  %BSA, 
nuclei were stained with 4′,6-Diamidino-2-phenylin-
dole dihydrochloride (DAPI, dilution 1.5:50000 in PBS-
CMF-1  %BSA) solution and the actin cytoskeleton with 
phalloidin (Phalloidin Alexa fluor® 660, Invitrogen; dilu-
tion 1:250 in PBS-CMF-1 %BSA,) for 5 min. Finally, the 
preparations were rinsed three times with PBS-CMF and 
mounted under coverslips with Prolong Antifade reagent 
(Invitrogen).
Images were acquired and processed with Zeiss 
Apotome and Axiovision software (Carl Zeiss, Jena, Ger-
many) using a 63x/1.4 objective lens. This system pro-
vides an optical slice view reconstructed from fluorescent 
samples (structured illumination microscopy).
Permeability of the barrier to a low‑molecular‑weight 
integrity marker
To assess the integrity of the BCSFB in vitro, its perme-
ability to Lucifer Yellow (LY, 457 Da, Ref. L0259, Sigma-
Aldrich) was measured in control filters and after each 
transmigration experiment. The quantity of LY having 
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crossed the BCSFB in  vitro was measured in the lower 
compartment after 1 h, using a microplate reader (Tecan 
Infinite M200 Multiwell reader, Tecan, Switzerland). For 
permeability coefficient (Pe) calculations, the method 
from Cecchelli et al. [30] was used.
Statistical analyses
The results were expressed as mean ±  SEM from three 
independent experiments, each performed in triplicates. 
Statistical significance was assessed by unpaired t-tests. 
A p value <0.05 was considered as significant. All statis-
tical analyses were performed using GraphPad Prism 5.0 
for Windows (GraphPad Software, San Diego, California, 
USA).
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Additional files
Additional file 1: Figure 1. Effect of a pretreatment of the HIBCPP layer 
with the actin microfilament‑disrupting agent Cytochalasin D on the 
transmigration rate of IMR32 and SH‑SY5Y neuroblastoma cell lines (a) 
and barrier integrity, as assessed by TEER (b) and dextran flux (c) measure‑
ments. Transmigration experiments were performed and transmigration 
rates were determined as described in Materials and Methods section (a). 
Before transmigration experiments, filters with HIBCPPs were incubated 
for 75 min with 1 µg.ml−1 Cytochalasin D (Sigma) diluted in serum‑free 
medium containing 0.5 % BSA (‘+ cytochalasin D’ condition). In parallel, 
control filters were incubated with serum‑free medium containing 0.5 % 
BSA (‘‑ cytochalasin D’ condition). The TEER was measured before the 
treatment and after the treatment to confirm break‑down of the barrier 
properties (b, ‘before’ and ‘cyto D’ conditions). All filters were then placed 
in new wells containing medium without Cytochalasin D, the transmigra‑
tion experiment was launched. 5 µl Dextran‑TexasRed (MW: 3000 Da, 
Life Technologies) were added to the upper compartment of the inserts 
together with IMR32 or SH‑SY5Y cells, in order to monitor permeability of 
HIBCPPs treated with and without cytochalasin D during the experiment 
(c). After 4 h of transmigration, the TEER was measured again (b, condition 
‘after’). TEER values increased again and the experiment was stopped. 
The fluid in the lower compartments was collected for determination of 
the amount of Dextran having crossed the barrier during the experiment 
by fluorescence measurement using a Tecan 200 M Infinite Multiwell 
reader (c). All results were expressed as mean ± SD from two independ‑
ent experiments, each performed in triplicates. Statistical significance 
was assessed by unpaired t‑tests. A p‑value < 0.05 was considered as 
significant. Statistical analyses were performed using GraphPad Prism 5.0 
for Windows (GraphPad Software, San Diego, California, USA).
Additional file 2: Figure 2. Three‑dimensional reconstruction from a 
basolateral point of view of Figure 2c. It shows that the transmigrated 
cancer cell is lying over a continuous tight junction, at the apical side of 
the barrier. Scale bar as indicated. 
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